Method of Administration Sample Clauses

Method of Administration. Patients will receive two intradermal injections of approximately 0.5 mL volume on the anterior or medial side of the same thigh. The general area of vaccination will be at a location midway between the inguinal ligament and the knee and will be administered in the same lymph node draining area. The vaccinations will be given every 21 days for 5 doses total. Intradermal vaccinations should be given in a method similar to the “PPD Skin Test” through a 26- or 27-gauge needle (3/8 inch) in the anterior thigh midway between the inguinal ligament and the knee. The whole 1 mL vaccination volume will be administered in 2 different sites approximately 5 cm (about 2 inches) apart from each other, by carefully injecting 500 μL (0.5 cc) at each vaccination site by intradermal injection per the diagram shown below. The vaccinations will be administered using sterile technique by a well-trained research nurse or trained study staff. The patient must be monitored for 1 hour after the vaccination for signs of any adverse reaction. • Cleanse the area by swabbing the skin (an approximately 4 to 5 inch circle) with alcohol pads. • Hold the skin taut before injecting. Place the 2 intradermal vaccinations in 2 quadrants of the cleansed circle. • As depicted below keep the syringe low and flat along the skin surface (inject with needle bevel side up). Inject 500 μL forming a nice “bleb” under the skin. • Slowly retract the needle and allow the “bleb” to resorb. Repeat 1 more time to completely administer the full 1.0 mL volume. Observe the patient and injection sites for 1 hour. • Place a 4x6 sterile gauze bandage over the site on the thigh to protect from irritation for 12 to 24 hours. • Any leakage of the dose onto the skin or inability to deliver the full 1 mL volume to the 2 sites should be noted in the eCRF. • Patients must be observed immediately after vaccinations for signs of an acute allergic reaction. If symptoms such as difficulty breathing, angioedema, diffuse and significant urticaria, and/or hypotension are observed, immediate emergency medical attention will be provided.
Sample 1Sample 2
AutoNDA by SimpleDocs
Method of Administration. The Ceding Company will report to AUL all risks reinsured hereunder by the preparation and submission to AUL of a monthly Statement. The statement shall include, but not be limited to, the information shown in Attachment 1. The Ceding Company may request facultative consideration on any risk written by the Ceding Company on the plans of insurance set out in Exhibit B, by mailing to AUL a Reinsurance Application Form (Attachment 3) properly completed as facultative. Along with reinsurance application, the Ceding Company shall forward copies of its application, medical examination, inspection report, and all other pertinent information. AUL will give the application for reinsurance its prompt consideration and communicate its decision on the risk to the Ceding Company. For risks facultatively reinsured hereunder, the Ceding Company shall also mail to AUL a completed Formal Reinsurance Cession, (Attachment 3), along with copies of all pertinent papers which have not previously been submitted to AUL.
Sample 1
Method of Administration. Mektovi is for oral use. The tablets are to be swallowed whole with water. They may be taken with or without food.
Sample 1
Method of Administration. Administrators have the ability to (i) set a Lyft Pass as a one-time or recurring benefit; (ii) set an expiration date and value for each Lyft Pass benefit; and (iii) include time, geofencing, and ride type restrictions.
Sample 1
Method of Administration. Budenofalk® 2mg rectal foam can be applied in the morning or evening. The canister is first fitted with an applicator and then shaken for about 15 seconds before the applicator is inserted into the rectum as far as comfortable. Note that the dose is only sufficiently accurate when the pump dome is held downwards as vertically as possible. To administer a dose of Budenofalk® 2mg rectal foam, the pump dome is fully pushed down and very slowly released. Following the activation the applicator should be held in position for 10-15 seconds before being withdrawn from the rectum. The best results are obtained when the intestine is evacuated prior to administration of Budenofalk® 2mg rectal foam.
Sample 1
Method of Administration. Budenofalk® 2mg rectal foam can be applied in the morning or evening. The attending physician determines the duration of use. An acute episode generally subsides after 6 to 8 weeks. Budenofalk® 2mg rectal foam should not be used after this time.
Sample 1
Method of Administration. The capsules containing the gastro-resistant granules should be taken before meals, swallowed whole with plenty of fluid (e.g. a glass of water). The duration of treatment in active Crohn’s Disease and in collagenous colitis should be limited to 8 weeks. The treatment with Budenofalk 3 mg should not be stopped abruptly, but withdrawn gradually (tapering doses). In the first week, the dosage should be reduced to two capsules daily, one in the morning, one in the evening. In the second week, only one capsule should be taken in the morning. Afterwards treatment can be stopped.
Sample 1
AutoNDA by SimpleDocs
Method of Administration. The following procedure is recommended for performing the PPD test: 95/102 113 [LOGO] The SILVX xxxdy -------------------------------------------------------------------------------- 1. The site of the test is the flexor surface of the forearm about 4 inches below the bend of the elbow. 2. The skin of the forearm is first cleansed with alcohol and allowed to dry.
Sample 1
Method of Administration. Tacrolimus ointment should be applied as a thin layer to affected areas of the skin and rubbed in gently. Tacrolimus ointment may be used on any part of the body, including xxxx, xxxx and flexure areas, except on mucous membranes. Tacrolimus ointment should not be applied under occlusion (dressings and bandages). Emollients should not be applied to the same area within 2 hours of applying tacrolimus ointment. Tacrolimus ointment is contraindicated: • in patients with a known hypersensitivity to the drug, other macrolactams or any of the excipients • in pregnant or breastfeeding women Tacrolimus ointment should not be used in: o congenital or acquired immunodeficiencies o patients on therapies that cause immunosuppression. o potentially malignant or pre-malignant skin lesions. o clinical infections at treatment sites o patients requiring occlusive dressings o patients with Xxxxxxxxx'x syndrome, lamellar ichthyosis, generalized erythroderma or cutaneous Graft Versus Host Disease. Treatment with tacrolimus may be associated with an increased risk of folliculitis and herpes viral infections (herpes simplex dermatitis, herpes simplex, Kaposi's varicelliform eruption). In the presence of these infections, the balance of risks and benefits associated with tacrolimus use should be evaluated. Tacrolimus is extensively metabolised in the liver and although blood concentrations are low following topical therapy, the ointment should be used with caution in patients with hepatic failure. Care should be exercised if applying tacrolimus to patients with extensive skin involvement over an extended period of time, especially in children. Patients with severe atopic dermatitis may have an increased risk of skin bacterial infections (e.g. impetigo) during treatment with tacrolimus ointment. Care should be taken to avoid contact with eyes and mucous membranes. If accidentally applied to these areas, the ointment should be thoroughly wiped off and/or rinsed off with water. As with any topical medicinal product, patients should wash their hands after application if the hands are not intended for treatment. Physicians should advise patients on appropriate sun protection measures, such as minimisation of the time in the sun, use of sunscreen product and covering the skin with appropriate clothing. The use of ultraviolet (UV) light from a solarium, therapy with UVB or UVA in combination with psoralens (PUVA) should be avoided during use of tacrolimus ointment. Cases of malignancie...
Sample 1

Related to Method of Administration

  • Method of Billing Consultant may submit invoices to the City for approval on a progress basis, but no more often than two times a month. Said invoice shall be based on the total of all Consultant’s services which have been completed to City’s sole satisfaction. City shall pay Consultant’s invoice within forty-five (45) days from the date City receives said invoice. Each invoice shall describe in detail, the services performed, the date of performance, and the associated time for completion. Any additional services approved and performed pursuant to this Agreement shall be designated as “Additional Services” and shall identify the number of the authorized change order, where applicable, on all invoices.

  • Method of Adjustment Calculation Agent Adjustment; notwithstanding anything in the 2002 Definitions to the contrary, the Calculation Agent may make an adjustment pursuant to Calculation Agent Adjustment to any one or more of the Base Amount, the Forward Price and any other variable relevant to the settlement or payment terms of the Transaction.

  • Grant Administration Grantee shall use the Grant funds only for the activities described in the approved Scope of Work. Grantee shall maintain financial records relating to the receipt and expenditure of all Grant funds in accordance with the terms set forth under this Agreement for a period of seven (7) years starting on the first day after final payment under the Agreement.

  • Method of Notice All notices shall be given (i) by delivery in person (ii) by a nationally recognized next day courier service, (iii) by first class, registered or certified mail, postage prepaid, (iv) by facsimile, or (v) by electronic mail] to the address of the OETC Contract Administrator or Contractor's Contract Coordinator or such other address as either party may specify in writing.

  • Method of Computation To determine the Adviser’s liability with respect to the Excess Amount, each month the Fund Operating Expenses for the Fund shall be annualized as of the last day of the month. If the annualized Fund Operating Expenses for any month exceeds the Operating Expense Limit of the Fund, the Adviser shall first waive or reduce its investment advisory fee for such month by an amount sufficient to reduce the annualized Fund Operating Expenses to an amount no higher than the Operating Expense Limit. If the amount of the waived or reduced investment advisory fee for any such month is insufficient to pay the Excess Amount, the Adviser shall also remit to the Fund an amount that, together with the waived or reduced investment advisory fee, is sufficient to pay such Excess Amount.

  • Method of Accounting The Company will use the method of accounting previously determined by the Members for financial reporting and tax purposes.

  • Method of Compensation It is understood by the parties that, insofar as pay is concerned, employees temporarily filling a position in a higher broadband level shall be paid according to the same compensation method as promoted employees pursuant to the Rules of the State Personnel System.

  • Administration of Medication CONTRACTOR shall comply with the requirements of California Education Code section 49423 when CONTRACTOR serves a student that is required to take prescription and/or over-the-counter medication during the school day. CONTRACTOR may designate personnel to assist the student with the administration of such medication after the student’s parent(s) provides to CONTRACTOR: (a) a written statement from a physician detailing the type, administration method, amount, and time schedules by which such medication shall be taken; and (b) a written statement from the student’s parent(s) granting CONTRACTOR permission to administer medication(s) as specified in the physician’s statement. CONTRACTOR shall maintain, and provide to LEA upon request, copies of such written statements. CONTRACTOR shall maintain a written log for each student to whom medication is administered. Such written log shall specify the student’s name; the type of medication; the date, time, and amount of each administration; and the name of CONTRACTOR’s employee who administered the medication. CONTRACTOR maintains full responsibility for assuring appropriate staff training in the administration of such medication consistent with physician’s written orders. Any change in medication type, administration method, amount or schedule must be authorized by both a licensed physician and parent.

  • Method of Communication Except as otherwise provided in this Agreement, all notices and communications hereunder shall be in writing, or by telephone subsequently confirmed in writing. Any notice shall be effective if delivered by hand delivery or sent via telecopy, recognized overnight courier service or certified mail, return receipt requested, and shall be presumed to be received by a party hereto (i) on the date of delivery if delivered by hand or sent by telecopy, (ii) on the next Business Day if sent by recognized overnight courier service and (iii) on the third Business Day following the date sent by certified mail, return receipt requested. A telephonic notice to the Administrative Agent as understood by the Administrative Agent will be deemed to be the controlling and proper notice in the event of a discrepancy with or failure to receive a confirming written notice.

  • Method of Allocation The Employer must specify in its Adoption Agreement the manner of allocating each annual Employer contribution to this Trust.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!